Medicus Pharma Ltd. (TSX.V: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. A wholly owned subsidiary of Medicus Pharma Ltd., SkinJect Inc., is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma, using  patented dissolvable doxorubicin-containing microneedle arrays (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant U.S. Patent was granted to the University of Pittsburgh and Carnegie Mellon University in 2018. The patents were granted in 2018 and are valid through 2040.